Jacobs Levy Equity Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Jacobs Levy Equity Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-36,500	Closed	-$98K	–	1048
2019 Q2	$98K	Sell	36,500 -280,595	-88%	-$829K	﹤0.01%	919
2019 Q1	$939K	Buy	317,095 +49,482	+18%	+$122K	0.01%	675
2018 Q4	$426K	Buy	267,613 +36,500	+16%	+$103K	0.01%	761
2018 Q3	$850K	Buy	231,113 +17,300	+8%	+$51.6K	0.01%	674
2018 Q2	$605K	Buy	213,813 +62,413	+41%	+$213K	0.01%	762
2018 Q1	$562K	Sell	151,400 -4,500	-3%	-$14.7K	0.01%	761
2017 Q4	$449K	Buy	+155,900	New	+$566K	0.01%	775

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jacobs Levy Equity Management's ACHN Position: Q3 2019 in Review

Jacobs Levy Equity Management sold out of Achillion Pharmaceuticals (ACHN) in Q3 2019, closing a stake of 36,500 shares — an estimated $98K sold.

Jacobs Levy Equity Management first reported a position in ACHN in Q4 2017 and held it in 7 quarters. The position peaked at $939K in Q1 2019. 122 funds tracked by Wall St. Rank hold ACHN as of Q3 2019.

Jacobs Levy Equity Management reported no remaining Achillion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Jacobs Levy Equity Management sold 36,500 Achillion Pharmaceuticals shares in Q3 2019, an estimated $98K.
Jacobs Levy Equity Management first reported a position in Achillion Pharmaceuticals in Q4 2017 and held it in 7 quarters.
Jacobs Levy Equity Management's Achillion Pharmaceuticals position peaked at $939K in Q1 2019.
122 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2019, filed 14 Nov 2019.